On May 19, 2025, HC Wainwright & Co. reaffirmed its positive outlook on Aldeyra Therapeutics (ALDX, Financial). Analyst Matthew Caufield reiterated the "Buy" rating for the stock, maintaining the target price at $10.00 USD.
This consistent rating from HC Wainwright & Co. reflects continued confidence in Aldeyra Therapeutics' potential growth and performance. The target price remains unchanged from the previous valuation, suggesting stability in the firm's market expectations for ALDX.
Investors and market watchers will likely keep an eye on Aldeyra Therapeutics as the reiterated "Buy" rating may influence trading behaviors and sentiments around the stock. The target price of $10.00 USD signifies the analyst's forecast for ALDX's potential value in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Aldeyra Therapeutics Inc (ALDX, Financial) is $8.29 with a high estimate of $11.00 and a low estimate of $6.00. The average target implies an upside of 283.60% from the current price of $2.16. More detailed estimate data can be found on the Aldeyra Therapeutics Inc (ALDX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Aldeyra Therapeutics Inc's (ALDX, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
